Isolated anti-Ro52 identifies a severe subset of Sjögren's syndrome patients.
Sjögren’s syndrome
anti-Ro52/TRIM21
autoantibodies
cryoglobulinaemia
rheumatoid factor, Ro/La
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2023
2023
Historique:
received:
04
12
2022
accepted:
24
02
2023
medline:
4
4
2023
entrez:
3
4
2023
pubmed:
4
4
2023
Statut:
epublish
Résumé
Serum autoantibodies targeting the SSA/Ro proteins are a key component of the classification criteria for the diagnosis of Sjögren's syndrome (SS). Most patients' serum reacts with both Ro60 and Ro52 proteins. Here we compare the molecular and clinical characteristics of patients diagnosed with SS with anti-Ro52 in the presence or absence of anti-Ro60/La autoantibodies. A cross-sectional study was performed. Patients in the SS biobank at Westmead Hospital (Sydney, Australia) that were positive for anti-Ro52 were included and stratified based on the absence (isolated) or presence (combined) of anti-Ro60/La, measured by line immunoassay. We examined clinical associations and the serological and molecular characteristics of anti-Ro52 using ELISA and mass spectrometry in serological groups. A total of 123 SS patients were included for study. SS patients with isolated anti-Ro52 (12%) identified a severe serological subset characterised by higher disease activity, vasculitis, pulmonary involvement, rheumatoid factor (RhF) and cryoglobulinaemia. Serum antibodies reacting with Ro52 in the isolated anti-Ro52 subset displayed less isotype switching, less immunoglobulin variable region subfamily usage and a lower degree of somatic hypermutation than the combined anti-Ro52 subset. In our cohort of SS patients, isolated anti-Ro52 represents a severe subset of SS, and is associated with the presence of cryoglobulinaemia. We therefore provide clinical relevance to the stratification of SS patients by their sero-reactivities. It is possible that the autoantibody patterns may be immunological epiphenomena of the underlying disease process, and further work is required to unearth the mechanisms of the differential clinical phenotypes.
Identifiants
pubmed: 37006271
doi: 10.3389/fimmu.2023.1115548
pmc: PMC10061105
doi:
Substances chimiques
Antibodies, Antinuclear
0
Autoantibodies
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1115548Informations de copyright
Copyright © 2023 Lee, Putty, Lin, Swaminathan, Suan, Chataway, Thurlings, Gordon, Wang and Reed.
Déclaration de conflit d'intérêts
JJW and RT are Guest Editors of Frontiers in Immunology. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Clin Exp Immunol. 1998 Feb;111(2):365-71
pubmed: 9486405
Int J Rheumatol. 2017;2017:3076017
pubmed: 28210273
Semin Arthritis Rheum. 2020 Oct;50(5):846-853
pubmed: 32896698
J Autoimmun. 2008 Nov;31(3):263-7
pubmed: 18511235
Clin Exp Rheumatol. 2021 Nov-Dec;39 Suppl 133(6):80-84
pubmed: 34665703
Ann Rheum Dis. 2017 Jan;76(1):9-16
pubmed: 27789466
Clin Exp Rheumatol. 2015 Jul-Aug;33(4 Suppl 91):S131-5
pubmed: 26315678
J Immunol. 2000 Aug 1;165(3):1626-33
pubmed: 10903773
Postgrad Med J. 2010 Feb;86(1012):79-82
pubmed: 20145055
Clin Exp Rheumatol. 2012 Sep-Oct;30(5):686-92
pubmed: 22704838
RMD Open. 2015 Feb 20;1(1):e000022
pubmed: 26509054
Arthritis Care Res (Hoboken). 2022 Sep 5;:
pubmed: 36063396
J Immunol. 2007 Jul 1;179(1):26-30
pubmed: 17579016
Clin Exp Immunol. 2018 Dec;194(3):273-282
pubmed: 30086185
Scand J Immunol. 1999 Jun;49(6):620-8
pubmed: 10354373
Ann Rheum Dis. 2002 Oct;61(10):929-33
pubmed: 12228166
Rheumatology (Oxford). 2019 Jul 1;58(7):1163-1167
pubmed: 30561748
Scand J Rheumatol. 2021 Nov;50(6):469-474
pubmed: 33851896
Rheumatol Int. 2017 Aug;37(8):1323-1333
pubmed: 28417151
Arthritis Rheum. 2010 Aug;62(8):2458-66
pubmed: 20506527
Arthritis Res Ther. 2017 Dec 6;19(1):269
pubmed: 29208023
Arthritis Rheum. 2010 May;62(5):1448-56
pubmed: 20131295
Lupus. 1998;7(3):202-6
pubmed: 9607645
Immunol Rev. 2022 May;307(1):101-115
pubmed: 35001403
Healthcare (Basel). 2021 Mar 23;9(3):
pubmed: 33807070
Nature. 2002 Apr 11;416(6881):603-7
pubmed: 11948342
Arthritis Rheum. 2008 Apr;58(4):1125-9
pubmed: 18383373
Ann Rheum Dis. 2002 Jun;61(6):554-8
pubmed: 12006334
J Clin Pathol. 2018 Jan;71(1):12-19
pubmed: 28663326
J Autoimmun. 2021 Nov;124:102724
pubmed: 34464814
Arthritis Care Res (Hoboken). 2013 Aug;65(8):1291-8
pubmed: 23335582
Immunol Med. 2021 Dec;44(4):252-262
pubmed: 33989125
Open Rheumatol J. 2015 Jun 26;9:36-45
pubmed: 26161156
Clin Exp Rheumatol. 2022 Dec;40(12):2310-1317
pubmed: 36200940
Blood. 2022 Oct 13;140(15):1738-1742
pubmed: 35661872
Arthritis Care Res (Hoboken). 2022 Sep;74(9):1559-1565
pubmed: 33742788
Cell. 2020 Mar 5;180(5):878-894.e19
pubmed: 32059783
Clin Rheumatol. 2022 Nov;41(11):3495-3501
pubmed: 35871174